F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

This is an interventional diagnostic trial for Bone Metastases focused on measuring bone metastasis, bone metastases, Sodium Fluoride, F18 Fluoride, bone scan Read More

Inclusion Criteria:

• Patient is ≥ 18 years old at the time of the drug administration (Patient may be male or female of any race / ethnicity.)
• Patient or patient's legally acceptable representative cognitively provides written informed consent
• Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast, lung or prostate cancer
• Patient is scheduled to undergo a conventional bone scan
• Patient is capable of complying with study procedures
• Patient is able to remain still for duration of imaging procedure (about one hour)
• Patient may have had a prior PET or PET/CT scan for staging/restaging.

Exclusion Criteria:

• Patient is < 18 years old at the time of the drug administration

• Patient is pregnant or nursing;

  • testing on site at the institution (urine or serum ßHCG) within 24 hours prior to the start of investigational product administration
  • obtaining surgical history (e.g., tubal ligation or hysterectomy)
  • confirming the subject is post menopausal, with a minimum 1 year without menses
• Patient has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete good quality data
• Patient has known bone metastases
• Patient has previously received [18F]NaF in the last thirty days